New breast cancer drug wins FDA approval after slashing progression risk by nearly 40%
The U.S. Food and Drug Administration has approved a new treatment for advanced breast cancer.Drugmaker Eli Lilly announced on Sept. 25 the approval of Inluriyo, an oral estrogen receptor antagonist, to treat adults with specific types of the disease.Those types include estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer.WEIGHT LOSS COULD BE JUST A PILL AWAY, STUDY OF NEW MEDICATION SUGGESTSThe once-daily […]